CD40 agonist mitazalimab + mFOLFIRINOX (mFFX) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Final efficacy analysis of the OPTIMIZE-1 study.

Journal of Clinical Oncology 2026

View at publisher
Authors: Teresa Mercade Macarulla, Emmanuel Mitry, R.A. Pazo Cid, I. Gallego Jiménez, Karen Paula Geboes, Ivan Borbath, Aurélien Lambert, Philippe Alexandre Cassier, H. Prenen, Jean-Frederic Blanc, Lorenzo Pilla, Jaime Feliú
+7 more Mercedes Rodríguez Garrote, Tom Moore, Ulla Holm Hansen, Karin Nordbladh, Peter Ellmark, Yago Pico de Coaña, Jean‐Luc Van Laethem
DOI: 10.1200/jco.2026.44.2_suppl.708
Cited by: 0

Abstract

708 Background: With a 5-year overall survival (OS) rate

Fields of Study & Subjects

Pancreatic and Hepatic Oncology Research Cancer Immunotherapy and Biomarkers Peptidase Inhibition and Analysis

Publication details

Journal / source
Journal of Clinical Oncology
Volume
44
Issue
2_suppl
Pages
708–708
Publication date
10 January 2026
Language
EN